Bratina P, Rapp K, Barch C, Kongable G, Donnarumma R, Spilker J, Daley S, Braimah J, Sailor S
University of Texas Health Science Center, Department of Neurology, Houston 77030, USA.
J Neurosci Nurs. 1997 Dec;29(6):356-60. doi: 10.1097/01376517-199712000-00004.
Stroke is a leading cause of death and disability among Americans. The recent US Food and Drug Administration approval of recombinant tissue plasminogen activator (rt-PA, Activase) for the treatment of acute ischemic stroke offers the first proven therapy to reverse or ameliorate stroke symptoms. rt-PA is thought to restore circulation in the patient with acute ischemic stroke by dissolving an occluding thrombus or embolus. A basic understanding of cerebral circulation and the mechanism by which stroke compromises brain tissue is fundamental to appreciating this new therapy. The importance of prompt stroke diagnosis and treatment cannot be underestimated.
中风是美国人死亡和残疾的主要原因。美国食品药品监督管理局最近批准重组组织型纤溶酶原激活剂(rt-PA,爱通立)用于治疗急性缺血性中风,这提供了首个经证实可逆转或改善中风症状的疗法。rt-PA被认为是通过溶解阻塞性血栓或栓子来恢复急性缺血性中风患者的血液循环。对脑循环以及中风损害脑组织的机制有基本的了解,是理解这种新疗法的基础。中风诊断和治疗及时性的重要性不可低估。